Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer Looks to Nematode Worms to Cure Cancer

In light of Bayer AG (BAYZF)’s shift out of the plastics business it is doubling down on cross-species research strategies. This slightly tenuous approach is to examine drug and chemical mechanisms not only in animals as compared to humans, but in plants as well, and try to apply them to human drug development. Based in […]

Read More »

Pfizer wins EU approval for $15 billion Hospira buy

U.S. drugmaker Pfizer (PFE.N) gained European Union antitrust approval on Tuesday for its proposed $15 billion acquisition of U.S. rival Hospira (HSP.N) after pledging to sell some drugs to allay competition concerns. “The approval is conditional on Pfizer divesting certain sterile injectable drugs, as well as its infliximab biosimilar drug, which is currently under development,” […]

Read More »

Regeneron raises Eylea sales forecast, shares at record

Regeneron Inc’s blockbuster eye drug, Eylea, showed no signs of a slowdown as the drugmaker raised the full-year sales forecast for its flagship product above at least four analysts’ expectation. The company’s shares rose to a record of $605.93 in early trading on Tuesday. U.S. sales of Eylea surged 58 percent to $655 million in […]

Read More »

Akorn Inc’s Hi-Tech Pharmacal infringes Allergan glaucoma drug patents

Akorn Inc’s Hi-Tech Pharmacal Co, Inc infringed three Allergan Inc patents on its Lumigan topical glaucoma treatment, a U.S. appeals court ruled on Tuesday. The U.S. Court of Appeals for the Federal Circuit also said five of Allergan’s Lumigan patents were valid. The case stems from lawsuits Allergan filed in 2011 against Hi-Tech, Novartis AG, […]

Read More »

Fitness experts warn of the pitfalls of going to exercise extremes

With challenging workouts from ultra-marathons to endurance events on obstacle courses all the rage, fitness experts say more and more weekend warriors are leaping into extreme activities before looking into the perils of overdoing it. The drive to push the body too far too fast can backfire in most unpleasant ways. Recent research studies suggest […]

Read More »

Minor League Baseball Takes the 2015 ALS Ice Bucket Challenge

WASHINGTON, Aug. 4, 2015 /PRNewswire-USNewswire/ — Minor League Baseball (MiLB) mascots and representatives, including MiLB President & CEO Pat O’Conner, accepted the ALS Ice Bucket Challenge, challenging all 160 teams to raise awareness and donations to fight the disease. ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that affects neurons (nerve cells) in the […]

Read More »

Horizon Pharma Files Lawsuit, Seeks Change of Depomed’s Board of Directors in Takeover Attempt

Irish drugmaker Horizon Pharma (HZNP) fired off a two-pronged maneuver including calling for a special shareholder’s meeting and filing as lawsuit as it continues to take over California-based rival Depomed, Inc. (DEPO).   On Monday the Dublin-based maker of drugs for pain and central nervous system conditions, called a special shareholders meeting seeking the removal […]

Read More »

CVS profit beats estimates on higher pharmacy sales, claims

CVS Health Corp’s profit beat estimates for the fifth straight quarter, boosted by higher pharmacy claims and strong sales in its business that provides medication and services for serious diseases such as multiple sclerosis and cancer. Revenue from the company’s pharmacy services business rose about 12 percent in the second quarter. The business, which includes […]

Read More »

Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy

LOUISVILLE, CO–(Marketwired – August 04, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to exclusively license GI-6207, a Tarmogen® product candidate targeting cancers that express carcinoembryonic antigen (CEA). GI-6207 is the second Tarmogen product candidate licensed by Celgene under the collaboration. Under […]

Read More »

Aetna profit beats as moderate medical costs help government plans

Aetna Inc (AET.N) on Tuesday reported a better-than-expected adjusted net profit for the second quarter and said “moderate” medical costs boosted the profitability of its government Medicare and Medicaid plans. The third-largest U.S. health insurer, which is in the process of buying rival Humana Inc (HUM.N), also raised its full-year forecast for adjusted net profit […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom